|Table of Contents|

Status and progress of treatment for locally advanced nasopharyngeal carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 02
Page:
337-341
Research Field:
Publishing date:

Info

Title:
Status and progress of treatment for locally advanced nasopharyngeal carcinoma
Author(s):
YANG Baoqing
The Third Department of Oncology,the First People's Hospital of Qinzhou，Guangxi Qinzhou 535099，China.
Keywords:
nasopharyngeal carcinoma; intensity modulated radiation therapy; chemotherapy; molecular targeted therapy; immune checkpoint inhibitor
PACS:
R739.63
DOI:
10.3969/j.issn.1672-4992.2021.02.034
Abstract:
Nasopharyngeal carcinoma is one of the common malignant tumors in South China.The initial diagnosis of advanced stage would be more than 75%.Radiotherapy or concurrent chemoradiotherapy is an important treatment method for nasopharyngeal carcinoma.In the era of intensity modulated radiation therapy(IMRT),the 5-year local control rate and 5-year survival rate of locally advanced nasopharyngeal carcinoma have significantly improved,while the treatment effect has reached the bottleneck.IMRT,induction chemotherapy,concurrent chemoradiotherapy,and anti-EGFR molecular targeted therapy are methods of treament for locally advanced nasopharyngeal carcinoma.Concurrent immune checkpoint inhibitor therapy is emerging in the treatment of locally advanced nasopharyngeal carcinoma,which will be advanced progess on prolonged survival time in the future.

References:

［1］梁锌，杨剑，高婷，等.中国鼻咽癌流行概况［J］.中国肿瘤，2016,25(11):835-840. LIANG X，YANG J，GAO T，et al.Nasopharynx cancer epidemiolgy in China［J］.China Cancer,2016,25(11):835-840.
[2]ZHANG L,HUANG Y,HONG S.et al.Gemcitabine plus cisplatin versus fluorourtourcil plus cisplatin in recurrence or metastatic nasopharyngeal carcinoma:A multicentre,randomized,open-label,phase 3 trial［J］.Lancet,2016,388(10054):1883-1892.
[3]孙建国．国产放疗设备集成应用专家共识-鼻咽癌同质化IMRT治疗篇［J］．中华放射肿瘤学杂志，2019，28(4)：242-249. SUN JG.Consensus on the integrated application of domestic radiotherapy epuipment-homogenized IMRT of nasopharyngeal carcinoma:Radiotherapy［J］.J Chin Oncol,2019，28(4)：242-249.
[4]N HODAPP.The ICRU Report 83：Prescrbing,recording,and reporting photon-beam intensity-modulated radiationtherapy(IMRT)［J］.Strahlenther Onkol，2012，188(1)：97-99.
[5]李晔雄，王绿化，高黎，等.肿瘤放疗学［M］.5版.北京：中国协和医科大学出版社，2018：7. LI YX,WANG LH,GAO L,et al.Radiation oncology［M］.5th ed.Beijing:Peking Union Medical College Press,2018：7.
[6] XIAO WW,HUANG SM,HAN F,et al.Local control,survival,and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy:long-term results of a phase 2 study［J］.Cancer,2011,117(9):1874-1883.
[7]ZHANG B.Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma:A systematic review and meta-analysis［J］.Oral Oncol,2015,51（11）：1041-1046.
[8]PENG H，CHEN L，ZHANG J，et al.Induction chemotherapy improved long-term outcomes of patients with locoregionally advanced nasophayngeal carcinoma:A propensity matched analysis of 5-year survival outcomes in the era of intensity-modulated radiontherapy［J］.J Cancer,2017,8(3):371-377.
[9]鲜枫，胡欣，张倩，等.放疗分别联合多西他赛、顺铂、替吉奥治疗局部晚期鼻咽癌的疗效比较［J］.现代肿瘤医学，2019，27（16）：2852-2855. XIAN F，HU X，ZHANG Q，et al.Comparison of radiotherapy respectively combined with docetaxel,cisplatin,or S-1 in the treatment of locally advanced nasopharyngeal carcinoma［J］.Modern Oncology，2019，27（16）：2852-2855.
[10] 杨保庆，梁家义，杨玲玲，等.局部晚期鼻咽癌诱导化疗后勾画靶区及OAR临床应用初探［J］.肿瘤学杂志，2016，22（10）：816-820. YANG BQ，LIANG JY，YANG LL，et al.Study on delineation gross tumor volume and organs at risk on the dose distribution and clinical treatment after induction chemotherapy for locally advanced nasopharyngeal carcinoma［J］.J Chin Oncol，2016，22（10）：816-820.
[11]ZHANG Y，CHEN L，HU GQ，et al.Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma［J］.N Eng J Med，2019，381（12）：1124-1135.
[12]SUN Y，LI WF，CHEN NY，et al．Induction chenmotherapy plus concurrent chemoradiotherapy versus concureent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma：A phase3，multicentre，randomized controlled trials［J］．Lancet Oncol,2016，17(11):1509-1520.
[13] 杨保庆，杨玲玲，王仁生，等.局部晚期鼻咽癌诱导化疗后勾画靶区对危及器官剂量及疗效影响［J］.中华肿瘤防治研究，2016,23（24）：1613-1618. YANG BQ，YANG LL，WANG RS，et al.Impact of delineation gross tumor volume and OAR on the dose distribution and clinical treatment outcome after induction chemotherapy for loco-regionally advanced nasopharyngeal carcinoma［J］.Chinese Journal of Cancer Prevention and Treatment，2016,23（24）：1613-1618.
[14]SUN XM，SU SF，CHEN CY，et al.Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma：An analysis of survival and treatment toxicities［J］.Radiother Oncol，2014，110(3):398-403.
[15]BLANCHARD P，LEE A，MARGUET S， et al．Chemotherapy and radiotherapy in nasopharyngeal carcinoma:An update of the MAC-NPC meta-analysis［J］.Lancet Oncol，2015，16(6)：645-655.
[16]SUN Y，LI WF，CHEN NY.et al．Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma:A phase 3,multicentre,randomised controlled trial［J］.Lancet Oncol，2016，17(11)：1509-1520.
[17]LI WF，CHEN NY，ZHANG N，et al.Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma:Long-term results of phase 3 randomized controlled trial［J］.Int J Cancer,2019,45:295-305.
[18] FOLPRECHT G,LUTZ P,SCHOFFSKI P,et al.Cetuximab and irinotecan / 5- fluorouracil / folinic acidis a safe combination for the firstline treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma［J］.Ann Oncol,2012,23(3):450.
[19] HUANG JF，ZHANG FZ，ZOU QZ，et al．Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma:Preliminary results from a phase Ⅱ clinical trial［J］．Oncotarget，2017，8(2):2457-2465．
[20]LIU ZG，ZHAO Y，TANG J，et al．Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma:A retrospective analysis［J］.Oncotarget，2016，7(17):24429-24435．
[21] ZHAO C,MIAO J,SHEN G,et al.Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy:A multicentre,open-label,phase II clinical trial［J］.Ann Oncol,2019,30(4):637-643.
[22]MAHONEY KM，RENNERT PD，FREEMAN GJ.Combination cancer immunotherapy and new immunomodulatory targets［J］.Nat Rev Drug Discov，2015，14（8）：561-584.
[23]BRAHMER JR，TYKODI SS，CHOW LQ，et al.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer［J］.N Engl J Med，2012，366（26）：2455-2465.
[24]MOY JD，MOSKOVITZ JM，FERRIS RL.Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma［J］.Eur J Cancer,2017,76：152-166.
[25]WALLE T,MONGE RM,CERWENKA A,et al.Radiation effects on antitumor immune responses:Current perspectives and challenges［J］.Therapeutic Advances in Medical Oncology,2018,10:1758834017742575.
[26]HWANG WL,PIKE LRG,ROYCE TJ,et al.Safety of combining radiotherapy with immune-checkpoint inhibition［J］.Nature Reviews Clinical Oncology,2018,15（8）：477-494.
[27]BOCKEL S,DURAND B,DEUTSCH E.Combining radiation therapy and cancer immune therapies:From preclinical findings to clinical applications［J］.Cancer/Radiotherapy,2018，22（6-7）：567-580.
[28]RODRGUEZ-RUIZ ME,VANPOUILLE-BOX C,MELERO I,et al.Immunological mechanisms responsible for radiation-induced abscopal effect［J］.Trends Immunol，2018，39（8）：644-655.
[29]PARK B，YEE C，LEE KM.The effect of radiation on the immune response to cancers［J］.Int J Mol Sci， 2014，15（1）： 927-943.
[30]张惠博，龚虹云，刘华丽，等.远隔效应的研究进展与临床意义［J］.肿瘤学杂志，2017，23（4）：321-326. ZHANG HB，GONG HY，LIU HL，et al.Research progress and clinical significance of abscopal effect of radiotherapy［J］.J Chin Oncol，2017，23（4）：321-326.
[31]SEGAL NH,OU SI,BALMANOUKIAN A,at el.Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma:Results from a phase I/II expansion cohort［J］.Eur J Cancer,2019,109:154-161.
[32] 江蓉，邱艳芬，王晖，等.PD-L1蛋白在鼻咽癌中的表达及其临床意义［J］.中国耳鼻咽喉颅底外科杂志，2018，24（6）：561-564,570. JIANG R，QIU YF，WANG H，et al.Expression of programmed cell death ligand-1 in nasopharyngeal carcinoma and its clinical significance［J］.Chinese Journal of Otorhinolaryngology-skull Base Surgery,2018，24（6）：561-564,570.
[33]LEE VH，LO AW，LEUNG CY,et al.Correlation of PD-L1 expression of tumor cells with survival outcomes after radical intensity-modulated radiation therapy for non-metastatic nasopharyngeal carcinoma［J］.PLoS One,2016,11(6):e0157969.
[34] HSU C,LEE SH,EJADI S,et al.Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand1-positive nasopharyngeal carcinoma:Results of the KEYNOTE-028 study［J］.Clin Oncol,2017,35(36):4050-4056.
[35] BBY M,LIM WT,GOH BC,et al.Antitumor activity of nivolumabin recurrent and metastatic nasopharyngeal carcinoma:an international,multicenter study of the Mayo Clinic phase 2 consortium (NCI-9742) ［J］.Clin Oncol,2018,36(14):1412-1418.
[36] FANG WF,YANG YP,MA YX,et al.Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma:Results from two single-arm,phase 1 trials［J］.Lancet Oncol,2018,19(10):1338-1350.
[37]HUANG ZL,LIU S,WANG GN,et al.The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma:A systematic review and meta-analysis［J］.Cancer Cell International,2019,19(1)：141.

Memo

Memo:
广西壮族自治区卫生厅自筹经费科研课题（编号：Z2012684）
Last Update: 1900-01-01